Cited 10 time in
Fabrication of albumin-Ti3C2 MXene quantum dots-based nanohybrids for breast cancer imaging and synergistic photo/chemotherapeutics
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Won, So Yeon | - |
| dc.contributor.author | Singhmar, Ritu | - |
| dc.contributor.author | Sahoo, Sumanta | - |
| dc.contributor.author | Kim, Hongmi | - |
| dc.contributor.author | Kim, Chul Min | - |
| dc.contributor.author | Choi, Soon Mo | - |
| dc.contributor.author | Sood, Ankur | - |
| dc.contributor.author | Han, Sung Soo | - |
| dc.date.accessioned | 2024-12-03T06:30:42Z | - |
| dc.date.available | 2024-12-03T06:30:42Z | - |
| dc.date.issued | 2025-01 | - |
| dc.identifier.issn | 0927-7765 | - |
| dc.identifier.issn | 1873-4367 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/74468 | - |
| dc.description.abstract | Advancement in the development of new materials with theranostic and phototherapeutic potential along with receptiveness to external stimuli has been persistently inspiring oncology research. Herein, titanium carbide-based MXene quantum dots (FHMQDs) have been synthesized and modified to take advantage of stimuli-responsive behavior and target specificity for breast cancer cells. With a size of around 3 nm, the developed FHMQDs demonstrate high fluorescent emission at around 460 nm. With ∼90 % encapsulation efficiency of doxorubicin (DOX), the developed system also offers rapid DOX release behavior when encountering an acidic pH (5.4). Further, the in vitro assessment of the developed FHMQDs on MDA-MB 231 breast cancer cells presents excellent target specificity to cancer cells which was reflected by its high cytotoxicity against cancer cells. Additionally, the outstanding photodynamic efficiency of FHMQDs due to excessive Reactive Oxygen Species (ROS) generating ability along with apoptosis promoting capability of FHMQDs in cancer cells demonstrates a synergistic approach in cancer theranostics. Encouragingly, the fabricated FHMQDs also exhibited fluorescent labelling and bioimaging capacity which makes it an incredible platform that ensures theranostic excellence in breast cancer research. © 2024 Elsevier B.V. | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Elsevier BV | - |
| dc.title | Fabrication of albumin-Ti3C2 MXene quantum dots-based nanohybrids for breast cancer imaging and synergistic photo/chemotherapeutics | - |
| dc.type | Article | - |
| dc.publisher.location | 네델란드 | - |
| dc.identifier.doi | 10.1016/j.colsurfb.2024.114207 | - |
| dc.identifier.scopusid | 2-s2.0-85203257335 | - |
| dc.identifier.wosid | 001327025000001 | - |
| dc.identifier.bibliographicCitation | Colloids and Surfaces B: Biointerfaces, v.245 | - |
| dc.citation.title | Colloids and Surfaces B: Biointerfaces | - |
| dc.citation.volume | 245 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Biophysics | - |
| dc.relation.journalResearchArea | Chemistry | - |
| dc.relation.journalResearchArea | Materials Science | - |
| dc.relation.journalWebOfScienceCategory | Biophysics | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Physical | - |
| dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
| dc.subject.keywordAuthor | Active targeting | - |
| dc.subject.keywordAuthor | Cancer | - |
| dc.subject.keywordAuthor | MXene | - |
| dc.subject.keywordAuthor | Photodynamic | - |
| dc.subject.keywordAuthor | Quantum dots | - |
| dc.subject.keywordAuthor | Theranostic | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
